Novartis Ag (NVSEF) Free Cash Flow (QoQ) (2009 - 2026)

Novartis Ag (NVSEF) Free Cash Flow (QoQ) (2009 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Novartis Ag - - -

Historic Data

Download Data
DateValue
Mar 31, 2026 -43.19%
Jun 30, 2025 2,653.94%
Mar 31, 2025 -96.70%
Dec 31, 2024 2,298.13%
Sep 30, 2024 -93.75%
Jun 30, 2024 2,162.11%
Mar 31, 2024 -96.73%
Jun 30, 2023 2,162.50%
Mar 31, 2023 -97.06%
Dec 31, 2022 2,483.71%
Sep 30, 2022 -94.49%
Dec 31, 2021 1,815.10%
Sep 30, 2021 -92.12%
Jun 30, 2021 1,710.16%
Mar 31, 2021 -96.49%
Dec 31, 2020 2,412.54%
Sep 30, 2020 -93.36%
Dec 31, 2019 29.13%
Sep 30, 2019 -89.47%
Jun 30, 2019 1,102.13%